VENUS Study: ViEw of HidradeNitis SuppUrativa by PortugueSe General Practitioners
Abstract
Introduction: Hidradenitis suppurativa (HS) is a chronic dermatosis with a large impact in patients’ quality of life and an estimated 7-year delay in diagnosis. The General Practitioner (GP) is usually the first doctor to assist the HS patient. The primary objective of this study is to describe the knowledge and clinical approach of HS by GPs.
Material and Methods: A cross-sectional study was conducted, based on the GPs answers to a questionnaire designed to evaluate their knowledge on HS.
Results: One hundred eighty seven questionnaires were considered valid for inclusion in the study. The majority (97.3%) of GPs correctly identified HS as the most likely diagnosis when confronted with a typical clinical history of the disease, and 84.5% associated HS with chronicity. The majority (84.0%) of GPs refers these patients, mostly to Dermatology (89.3%). The majority of GPs also considered that a surgical approach may not be curative (94.1%) and 15.0% considered that biological agents might be indicated. We compared the answers of 2 groups: group A, n=100, with <5 years of clinical practice and group B, n=84, with ≥5 years. Group A associated more HS with tobacco use and obesity than group B (p=0.013 and p=0.006, respectively). A multidisciplinary approach was also more frequently selected by group A (p=0.004).
Conclusion: This pilot study shows that the view of Portuguese GPs about HS can be improved. There are significant differences concerning knowledge on HS between GPs with less than 5 years of clinical practice and the more experienced ones. This study can help to direct differential future educational actions.
Downloads
References
Prens E, Deckers I. Pathophysiology of hidradenitis suppurativa: An update. J Am Acad Dermatol. 2015;73:S8-11.
Egeberg A, Gislason GH, Hansen PR. Risk of Major Adverse Cardiovascular Events and All-Cause Mortality in Patients With Hidradenitis Suppurativa. JAMA Dermatol. 2016;152:429-434.
Pescitelli L, Ricceri F, Prignano F. Hidradenitis suppurativa and associated diseases. G Ital Dermatol Venereol. 2018;153:8-17.
Kridin K, Shani M, Schonmann Y, Fisher S, Shalom G, Comaneshter D, et al. Psoriasis and Hidradenitis Suppurativa: A Large-scale Population-based Study. J Am Acad Dermatol. 2018.
Rondags A, van Straalen KR, Arends S, van der Zee HH, Prens EP, Spoorenberg A, et al. High prevalence of clinical spondyloarthritis features in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2019;80:551-554 e551.
Peris K, Lo Schiavo A, Fabbrocini G, Dini V, Patrizi A, Fusano M, et al. HIDRAdisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2019;33:766-773.
Deckers IE, Kimball AB. The Handicap of Hidradenitis Suppurativa. Dermatol Clin. 2016;34:17-22.
Rondags A, van Straalen KR, van Hasselt JR, Janse IC, Ardon CB, Vossen A, et al. Correlation of the refined Hurley classification for hidradenitis suppurativa with patient-reported quality of life and objective disease severity assessment. Br J Dermatol. 2018.
Huilaja L, Tiri H, Jokelainen J, Timonen M, Tasanen K. Patients with Hidradenitis Suppurativa Have a High Psychiatric Disease Burden: A Finnish Nationwide Registry Study. J Invest Dermatol. 2018;138:46-51.
Ingram JR, Jenkins-Jones S, Knipe DW, Morgan CLI, Cannings-John R, Piguet V. Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa. Br J Dermatol. 2018;178:917-924.
Shavit E, Dreiher J, Freud T, Halevy S, Vinker S, Cohen AD. Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2015;29:371-376.
Thorlacius L, Cohen AD, Gislason GH, Jemec GBE, Egeberg A. Increased Suicide Risk in Patients with Hidradenitis Suppurativa. J Invest Dermatol. 2018;138:52-57.
Theut Riis P, Lindso Andersen P, Jemec GB. Arguments for a national questionnaire-based screening for hidradenitis suppurativa in Denmark. Acta Dermatovenerol Alp Pannonica Adriat. 2018;27:115-120.
Benhadou F, Theut Riis P, Njimi HH, Jemec GBE, del Marmol V. Hidradenitis Suppurativa in General Practice: A Pilot Study. J Gen Pract (Los Angel). 2015;3:207.
Napolitano M, Megna M, Timoshchuk EA, Patruno C, Balato N, Fabbrocini G, et al. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. Clinical, cosmetic and investigational dermatology. 2017;10:105-115.
Dufour DN, Emtestam L, Jemec GB. Hidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease. Postgrad Med J. 2014;90:216-221; quiz 220.
Vekic DA, Cains GD. Hidradenitis suppurativa - Management, comorbidities and monitoring. Aust Fam Physician. 2017;46:584-588.
Blok JL, Spoo JR, Leeman FW, Jonkman MF, Horvath B. Skin-Tissue-sparing Excision with Electrosurgical Peeling (STEEP): a surgical treatment option for severe hidradenitis suppurativa Hurley stage II/III. J Eur Acad Dermatol Venereol. 2015;29:379-382.
Gulliver W, Zouboulis CC, Prens E, Jemec GB, Tzellos T. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord. 2016;17:343-351.
Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, et al. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157:846-855.
Kimball AB, Sundaram M, Shields AL, Hudgens S, Okun M, Foley C, et al. Adalimumab alleviates skin pain in patients with moderate-to-severe hidradenitis suppurativa: Secondary efficacy results from the PIONEER I and PIONEER II randomized controlled trials. J Am Acad Dermatol. 2018;79:1141-1143.
Kyriakou A, Trigoni A, Galanis N, Sotiriadis D, Patsatsi A. Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data. Dermatol Reports. 2018;10:7859.
Calao M, Wilson JL, Spelman L, Billot L, Rubel D, Watts AD, et al. Hidradenitis Suppurativa (HS) prevalence, demographics and management pathways in Australia: A population-based cross-sectional study. PLoS One. 2018;13:e0200683.
Karagiannidis I, Nikolakis G, Sabat R, Zouboulis CC. Hidradenitis suppurativa/Acne inversa: an endocrine skin disorder? Rev Endocr Metab Disord. 2016;17:335-341.
Saunte DM, Boer J, Stratigos A, Szepietowski JC, Hamzavi I, Kim KH, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173:1546-1549.
Alavi A, Lynde C, Alhusayen R, Bourcier M, Delorme I, George R, et al. Approach to the Management of Patients With Hidradenitis Suppurativa: A Consensus Document. J Cutan Med Surg. 2017;21:513-524.
Marasca C, Annunziata MC, Cacciapuoti S, Cantelli M, Martora F, Scotti S, et al. A Dermatological Questionnaire for General Practitioners with a Focus on Hidradenitis Suppurativa. Open Access Maced J Med Sci. 2018;6:1902-1905.
Bettoli V, Pasquinucci S, Caracciolo S, Piccolo D, Cazzaniga S, Fantini F, et al. The Hidradenitis suppurativa patient journey in Italy: current status, unmet needs and opportunities. J Eur Acad Dermatol Venereol. 2016;30:1965-1970.
Tiri H, Jokelainen J, Timonen M, Tasanen K, Huilaja L. Substantially reduced life expectancy in patients with hidradenitis suppurativa: a Finnish nationwide registry study. Br J Dermatol. 2018.
Copyright (c) 2020 Journal of the Portuguese Society of Dermatology and Venereology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles in this journal are Open Access under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
